Jazz Pharma Plc (JAZZ)

Apr 23, 2025, 4:15 PM EDT - 9 hours ago

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Apr 22, 2025, 4:15 PM EDT - 1 day ago

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Apr 21, 2025, 4:05 PM EDT - 2 days ago

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Apr 9, 2025, 3:59 PM EDT - 14 days ago

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 8, 2025, 7:04 PM EDT - 15 days ago

Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case

Mar 26, 2025, 4:15 PM EDT - 4 weeks ago

Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 7:30 AM EDT - 5 weeks ago

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting

Mar 10, 2025, 10:33 PM EDT - 6 weeks ago

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

CMRX

Mar 5, 2025, 8:41 AM EST - 7 weeks ago

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline

CMRX

Mar 5, 2025, 7:14 AM EST - 7 weeks ago

Jazz Pharmaceuticals to buy Chimerix for $935 million

CMRX

Mar 5, 2025, 7:00 AM EST - 7 weeks ago

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

CMRX

Feb 26, 2025, 3:15 PM EST - 2 months ago

Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab

Feb 25, 2025, 9:20 PM EST - 2 months ago

Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:05 PM EST - 2 months ago

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

Feb 20, 2025, 4:15 PM EST - 2 months ago

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Feb 11, 2025, 4:15 PM EST - 2 months ago

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

Jan 22, 2025, 12:29 PM EST - 3 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT ONC XBI ZYME

Jan 13, 2025, 12:56 PM EST - 3 months ago

3 Oversold Biotech Names

AVDL FOLD VKTX XBI

Dec 23, 2024, 12:53 PM EST - 4 months ago

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Dec 17, 2024, 4:15 PM EST - 4 months ago

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 4:05 PM EST - 4 months ago

Jazz Pharmaceuticals Announces CEO Succession Plan

Dec 6, 2024, 4:05 PM EST - 4 months ago

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Dec 5, 2024, 7:45 AM EST - 4 months ago

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Dec 4, 2024, 4:15 PM EST - 5 months ago

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Dec 3, 2024, 7:49 AM EST - 5 months ago

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Nov 20, 2024, 7:59 PM EST - 5 months ago

Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment

Nov 20, 2024, 7:19 PM EST - 5 months ago

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 19, 2024, 4:05 PM EST - 5 months ago

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Nov 6, 2024, 7:31 PM EST - 6 months ago

Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 6:15 PM EST - 6 months ago

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?

Nov 6, 2024, 4:05 PM EST - 6 months ago

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Oct 31, 2024, 4:05 PM EDT - 6 months ago

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Oct 23, 2024, 4:15 PM EDT - 6 months ago

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

Oct 16, 2024, 8:39 AM EDT - 6 months ago

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 15, 2024, 11:50 AM EDT - 6 months ago

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer

Oct 15, 2024, 7:30 AM EDT - 6 months ago

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Oct 4, 2024, 9:00 AM EDT - 7 months ago

Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market

Sep 16, 2024, 7:30 AM EDT - 7 months ago

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

Sep 9, 2024, 7:58 AM EDT - 8 months ago

Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

Sep 5, 2024, 7:30 AM EDT - 8 months ago

Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024

Sep 4, 2024, 12:00 AM EDT - 8 months ago

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Sep 3, 2024, 7:00 AM EDT - 8 months ago

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Aug 22, 2024, 4:05 PM EDT - 8 months ago

Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Aug 21, 2024, 4:15 PM EDT - 8 months ago

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Jul 31, 2024, 7:40 PM EDT - 9 months ago

Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:05 PM EDT - 9 months ago

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance

Jul 25, 2024, 4:05 PM EDT - 9 months ago

Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

Jul 22, 2024, 7:45 AM EDT - 9 months ago

Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026

Jul 17, 2024, 4:15 PM EDT - 10 months ago

Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024

Jul 9, 2024, 7:45 AM EDT - 10 months ago

Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer